Diabetes Australia welcomes the Federal Authorities’s resolution to ban replicas of Ozempic and different weight reduction drugs following security issues.
Pharmacies compounding their very own variations of those drugs have been ordered to cease manufacturing from October 1, 2024.
The brand new rules will take away glucagon-like peptide-1 receptor agonists (GLP-1RAs), a lot of which declare to be replicas of Ozempic or Mounjaro, from the pharmacy compounding exemption.
Diabetes Australia understands the numerous issues of Australians dwelling with sort 2 diabetes concerning the ongoing international scarcity of Ozempic particularly, and can proceed to advocate for prioritised entry for folks dwelling with diabetes.
Nonetheless, on the subject of compounded variations, the well being and wellbeing of the group should be crucial consideration.
The compounded GLP-1RA merchandise the federal government has banned haven’t been evaluated by the TGA for security, high quality and efficacy. When a medication is compounded, it might have a distinct power and completely different substances from related medicines accredited by the TGA.
Diabetes Australia has advocated for the Therapeutic Items Administration (TGA) to analyze the shortages of various diabetes-related medicines and merchandise in recent times and redouble efforts to make sure Australians might be assured that provide chains are enough to fulfill their wants.
Extra details about the security of those merchandise might be discovered on the TGA web site.
